The regulatory T cells (Tregs), a subset of immune regulatory cells with the capacity to trigger immunological tolerance, are present in the tumor immune microenvironment, which is a complex ecosystem made up of many different types of cells and chemicals. By inhibiting the activity of other immune cells, Treg maintain immunological homeostasis and self-tolerance under normal circumstances. The immunomodulatory ability of Treg is used to suppress the antitumor immune response when tumors are present, which accelerates the growth and spread of the tumor.
Recent studies have shown that specific signaling molecules present in the tumor immune microenvironment can induce reprogramming of inflammatory Treg. This reprogramming may lead to a shift of inflammatory Treg from a normal immune regulatory state to a state that promotes tumor development. Additionally, inflammatory Treg are affected by factors produced by other immune cells and tumor cells in the tumor microenvironment. Treg also appear enlarged in the peripheral blood of cancer patients and express checkpoint molecules in high quantities, making Treg a direct target for immunotherapy. Anti-PD-1/PD-L1 medications are now utilized in immunotherapy to promote immune clearance of tumor cells by preventing signaling between immune cells and tumor cells. These medications can also boost inflammatory Treg activity, which negates their impact on the anti-tumor immune response. As a result, a hot topic of current research is the creation of novel tumor immunotherapy techniques to combat Treg reprogramming.
In conclusion, the reprogramming of inflammatory Treg in the tumor immune microenvironment is a complex process that can have a significant impact on tumor growth and immunotherapy. Therefore, this research theme aims to provide an in-depth understanding of the reprogramming mechanism of inflammatory Treg, explore new therapeutic strategies, and propose future directions in related fields.
We welcome submissions of original studies, brief research reports, reviews, mini-reviews, methods, perspectives, and opinion articles focusing on, but not limited to, the following topics:
1. Regulation of Treg cell number and function
2. Interaction of Treg cells with other immune cells
3. A deeper understanding of the reprogramming mechanism of inflammatory Treg
4. Immunotherapeutic strategies for the reprogramming of inflammatory Treg
5. Development of new assays to detect the presence and number of inflammatory Treg
6. Epigenetic regulation of Treg cells
The regulatory T cells (Tregs), a subset of immune regulatory cells with the capacity to trigger immunological tolerance, are present in the tumor immune microenvironment, which is a complex ecosystem made up of many different types of cells and chemicals. By inhibiting the activity of other immune cells, Treg maintain immunological homeostasis and self-tolerance under normal circumstances. The immunomodulatory ability of Treg is used to suppress the antitumor immune response when tumors are present, which accelerates the growth and spread of the tumor.
Recent studies have shown that specific signaling molecules present in the tumor immune microenvironment can induce reprogramming of inflammatory Treg. This reprogramming may lead to a shift of inflammatory Treg from a normal immune regulatory state to a state that promotes tumor development. Additionally, inflammatory Treg are affected by factors produced by other immune cells and tumor cells in the tumor microenvironment. Treg also appear enlarged in the peripheral blood of cancer patients and express checkpoint molecules in high quantities, making Treg a direct target for immunotherapy. Anti-PD-1/PD-L1 medications are now utilized in immunotherapy to promote immune clearance of tumor cells by preventing signaling between immune cells and tumor cells. These medications can also boost inflammatory Treg activity, which negates their impact on the anti-tumor immune response. As a result, a hot topic of current research is the creation of novel tumor immunotherapy techniques to combat Treg reprogramming.
In conclusion, the reprogramming of inflammatory Treg in the tumor immune microenvironment is a complex process that can have a significant impact on tumor growth and immunotherapy. Therefore, this research theme aims to provide an in-depth understanding of the reprogramming mechanism of inflammatory Treg, explore new therapeutic strategies, and propose future directions in related fields.
We welcome submissions of original studies, brief research reports, reviews, mini-reviews, methods, perspectives, and opinion articles focusing on, but not limited to, the following topics:
1. Regulation of Treg cell number and function
2. Interaction of Treg cells with other immune cells
3. A deeper understanding of the reprogramming mechanism of inflammatory Treg
4. Immunotherapeutic strategies for the reprogramming of inflammatory Treg
5. Development of new assays to detect the presence and number of inflammatory Treg
6. Epigenetic regulation of Treg cells
